⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5812083 | 0.61 | — | — | |
| SCHEMBL8578503 | 0.61 | — | — | |
| SCHEMBL16756468 | 0.60 | — | — | |
| SCHEMBL2034698 | 0.59 | — | — | |
| SCHEMBL13946994 | 0.58 | NOS3 (0.42) | — | |
| SCHEMBL6207737 | 0.57 | — | — | |
| SCHEMBL8881049 | 0.57 | — | — | |
| SCHEMBL1983842 | 0.56 | — | — | |
| SCHEMBL3224313 | 0.56 | CA1 (0.32) | — | |
| SCHEMBL15957272 | 0.56 | CA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946023-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | claimed |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3984997-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3489230-B1 | CHEMICAL COMPOUND OF ISOCITRATE DEHYDROGENASE INHIBITOR, AND APPLICATION THEREOF | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2021-12-08 | — | — | EP | disclosed |
| EP-3406608-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | LES LABORATOIRES SERVIER SAS (FR) | 2021-09-15 | — | — | EP | disclosed |
| EP-3019484-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | LES LABORATOIRES SERVIER SAS (FR) | 2021-09-08 | — | — | EP | disclosed |
| US-10961222-B2 | Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2021-03-30 | — | — | US | disclosed |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20160159771-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
| EP-3019484-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-3019483-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-3019480-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | Agios Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006591-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015003640-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015003641-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2800743-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102431-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |